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Background: The sulphadoxine/pyrimethamine (SDX/PYR) combination had been chosen to treat uncomplicated
falciparum malaria in Malaysia for more than 30 years. Non-silent mutations in dihydrofolate reductase (dhfr) and
dihydropteroate synthase (dhps) genes are responsible for the resistance to pyrimethamine and sulphadoxine,
respectively. This study reports the mutational analysis of pfdhfr and pfdhps in single Plasmodium falciparum
infection isolates from the interior division of Sabah, Malaysian Borneo.
Methods: A total of 22 P. falciparum single infection isolates collected from two districts of the interior division of
Sabah from February to November 2010 were recruited for the mutational study of pfdhfr and pfdhps. Both genes
were amplified by nested PCR prior to DNA sequencing and mutational analysis.
Results: A total of three pfdhfr and four pfdhps alleles were identified. The most prevalent pfdhfr allele is ANRNL
(86%) involving triple mutation at position 108(S to N), 59(C to R) and 164(I to L). In pfdhps, two novel alleles,
SGTGA (73%) and AAKAA (5%) were identified. Alleles involving triple mutation in both pfdhfr (ANRNL) and pfdhps
(SGTGA), which were absent in Sabah in a study conducted about 15 years ago, are now prevalent.
Conclusions: High prevalence of mutations in SDX/PYR associated drug resistance genes are reported in this study.
This mutational study of pfdhps and pfdhfr indicating that SDX/PYR should be discontinued in this region.Background
Plasmodium falciparum, which causes the most severe
form of malaria, is found mainly in the tropical and
subtropical regions including Sabah, Malaysian Borneo.
The spread of resistance to anti-malarial drugs poses
an important health problem. Chloroquine-resistant
P. falciparum was first reported in Malaysia in 1966 and
the sulphadoxine-pyrimethamine (SDX/PYR) (Fansidar®)
combination replaced chloroquine in 1979 as first-line
treatment for uncomplicated falciparum malaria in
Malaysia. The combination of pyrimethamine and sulpha-
doxine gives a synergistic action against P. falciparum by
inhibiting the dihydrofolate reductase and dihydropteroate
synthase enzymes in the folate biosynthesis pathway,* Correspondence: sophialau@ums.edu.my
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reproduction in any medium, provided the orrespectively [1,2]. Mutations in the genes encoding for
dihydrofolate reductase (dhfr) and dihydropteroate
synthase (dhps) are associated with resistance to SDX/
PYR [3].
In Malaysia, artemisinin combination therapy (ACT)
is currently being used as the first-line therapy for
falciparum malaria. ACT in Sabah consists of either
arthemether/lumefantrine or artesunate/mefloquine. This
is the first choice for the treatment of uncomplicated
P. falciparum infections in Sabah according to the
State treatment policy guidelines. However, despite this
policy, SDX/PYR combination is still occasionally used
by field workers to treat P. falciparum as presumptive
treatment for patients with suspected malaria who live
deep in the interior where a timely microscopy result
for malaria parasites may not be possible. Besides,
SDX/PYR combination is also sometimes used for
malaria prophylaxis in this region.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions in parasite molecules targeted by anti-malarial drugs
may offer better tools for monitoring drug resistance. In
vitro resistance of P. falciparum to PYR is primarily
conferred by a non-synonymous point mutation at
S108N and is progressively enhanced by mutations at
residue N51I and/or C59R of pfdhfr. An additional
mutation at I164L is associated with high-level clinical
resistance to SDX/PYR [4,5]. In pfdhps, point mutations
at A437G and K540E are considered responsible for
SDX resistance. It was thought that the point mutation
at 437 is the first event and is associated with a decreased
response to SDX [3,6]. Mutations at A581G and A613S in
the background of A437G were shown to associate with
high clinical resistance to SDX/PYR in South America and
Southeast Asia [5,7].
A large-scale study on the clinical efficacy of P. falciparum
malaria to SDX/PYR in Peninsular Malaysia conducted
in mid 1990s, reported 47% of the study isolates were
resistant to SDX/PYR [8]. A subsequent molecular
study reported 87% of P. falciparum had triple muta-
tions in pfdhfr and all isolates having point mutation at
codon A437G of pfdhps as indication of drug pressure,
accompanied by 81% point mutation at codon A581G
indicating reduced in vitro responsiveness of SDX [4].
The authors speculated that SDX/PYR might be still
effective in treating uncomplicated P. falciparum mal-
aria in Sabah due to most of the isolates having two or
less dhfr mutations. An increasing number of imported
cases of malaria as a result of worldwide travel and the
use of migrant work forces to and from the neighbour-
ing endemic countries have been reported in Sabah.
This makes Sabah vulnerable to the introduction of
drug resistant malaria and a reassessment of molecular
markers associated with P. falciparum resistance would
be timely. In this study, point mutations at pfdhfr and
pfdhps genes in P. falciparum isolates from the Interior
Division of Sabah, Malaysian Borneo were typed.Methods
Study sites and sample collections
A total of 22 P. falciparum single infection samples out of
243 total samples collected from the districts of Keningau,
and Nabawan in the interior division of Sabah, Malaysian
Borneo from February to November in 2010, were ana-
lyzed in this study. Ethical clearance was obtained from
the Ethical Committee of Ministry of Health Malaysia and
the Ethical Committee of Universiti Malaysia Sabah prior
Blood samples of approximately 25 μl were collected on
chromatography paper (Whatman 3MM) and dried before
storage in an individual plastic bag for sample collection.
Patients’ verbal and written consent were obtained before
their blood was taken. Sample collection and microscopicexamination was carried out by qualified medical labora-
tory staff at the respective hospitals.
Detection of mutations in pfdhfr and pfdhps
Genomic DNA was extracted using QIAmp® DNA
Mini Kit (QIAGEN, Hilden, Germany), according to
the manufacturer’s recommendation. Plasmodium species
were identified by nested-PCR using genus and species-
specific primers based on the small subunit ribosomal
RNA gene (ssrRNA). Single P.falciparum infections were
recruited in this study.
pfdhfr was amplified in nested PCR according to previ-
ously described method with minor modifications [9].
Primary round amplification comprised of 4 μl DNA tem-
plate, 0.25 μM each primers, 1.5 mM MgCl2, 200 μM
dNTPs, 1× PCR buffer, and 2.5 U of Taq in a 20 μl reac-
tions. Cycling conditions were performed as follow; 94°C
for 3 min, followed by 45 cycles of 94°C for 30 sec, 45°C
for 45 sec, and 72°C for 45 sec and finally 72°C for 5 min.
Nested PCR was performed with 2 μl DNA template from
the first round PCR product, 0.25 μM primers, 1.5 mM
MgCl2, 200 μM dNTPs, 1× PCR buffer, and 1 U of Taq in
a 20 μl reactions. The PCR was carried at 94°C for 3 min,
followed by 40 cycles at 94°C for 1 min, 45°C for 1 min,
72°C for 1 min and finally 72°C for 10 min.
Amplification of pfdhps was performed in nested PCR
according to previously described method with minor
modifications [10]. First round of PCR was carried out
in a 20 μl reaction containing 4 μl template, 0.25 μM
primers, 2.5 mM MgCl2, 200 μM dNTPs, 1× PCR buffer,
and 2.5 U of Taq at the following PCR conditions, 94°C
for 5 min, followed by 30 cycles 94°C for 55 sec, 45°C
for 45 sec, 72°C for 45 sec and finally 72°C for 5 min.
Nested PCR comprising 2 μl DNA template from the first
round PCR product, 0.25 μM primers, 1.5 mM MgCl2,
200 μM dNTPs, 1× PCR buffer, and 1.0 U of Taq in a
20 μl reaction. PCR was carried out at 94°C for 3 min,
followed by 40 cycles at 94°C for 1 min, 45°C for 1 min,
72°C for 1 min and 72°C for 10 min. Primer sequences for
nested PCR amplification of pfdhps and pfdhfr is shown in
Table 1.
PCR products were purified using QIAquick Gel
Extraction Kit (QIAGEN, Hilden, Germany) prior to
DNA sequencing. Detection of the mutations was per-
formed using the MEGA version 5 through comparative
analysis with the wild type sequence (GenBank accession
numbers are XM_001351443 and Z30654 for pfdhfr and
pfdhps, respectively). Single nucleotide polymorphisms
were verified through the bidirectional sequencing.
Results
Mutational analysis of pfdhfr
Based on the analysis of 5-codon alleles in pfdhfr, the wild
type allele, ANCSI was absent in the 22 P. falciparum
Table 1 Primer sequence for the amplification of pfdhfr and pfdhps
PCR reaction Primer pair sequence Expected size Reference
pfdhfr Nest 1 Pfdhfr_D1 5′ TTTATATTTTCTCCTTTTTA 3′ 718 bp [9]
Pfdhfr_D2 5′ CATTTTATTATTCGTTTTCT 3′
Nest 2 Pfdhfr_M1 5′ TTTATGATGGAACAAGTCTGC 3′ 648 bp
Pfdhfr_M5 5′ AGTATATACATCGCTAACAGA 3′
pfdhps Nest 1 Pfdhps_N185 5′ TGATACCCGAATATAAGCATAATG 3′ 1031 bp [10]
Pfdhps_N218 5′ ATAATAGCTGTAGGAAGCAATTG 3′
Nest 2 Pfdhps_Rc 5′GGTATTTTTGTTGAACCTAAACG 3′ 728 bp
Pfdhps_Rd 5′ATCCAATTGTGTGATTTGTCCAC 3′
Lau et al. Malaria Journal 2013, 12:445 Page 3 of 5
http://www.malariajournal.com/content/12/1/445isolates in the interior division of Sabah. Three different
alleles, namely ANRNL, ANRNI and AIRNI were detected
(Table 2a). The most prevalent allele in this study is
ANRNL (86.4%), which was absent in previous study
conducted in Sabah about 15 years ago [4]. All isolates
had mutation at position S108N and C59R accompanied
by 86.4% (n = 19) mutation at I164L. Approximately
9.1% (n = 2) of the total isolates showing pfdhfr double
mutations at position S108N and C59R alone (ANRNI).
One isolate from this region had additional mutation at
N51I, which has never been reported in Sabah, giving rise
to allele AIRNI. This allele was prevalent in P. falciparum
isolates from Kelantan, Peninsular Malaysia where clinical
resistance to SDX/PYR has been reported in various
locations [4].
Mutational analysis of pfdhps
Four alleles of pfdhps namely SGTGA, SGKGA, SGKAA
and AAKAA but not the wild type allele SAKAA, were
identified in this study (Table 2b). SGTGA is the most
prevalent allele which present in 72.7% (n = 16) of the total
study isolates. Only 13.6% (n = 3) of the P. falciparumTable 2 Dihydrofolate reductase (dhfr) and
dihydropteroate synthase (dhps) alleles in Plasmodium
falciparum isolates from the interior division of Sabah,
Malaysian Borneo
(a) pfdhfr amino acid position Prevalence (%)
16 51 59 108 164 n = 22
A N R N L 86.4
A I R N I 4.5
A N R N I 9.1
(b) pfdhps amino acid position Prevalence (%)
436 437 540 581 613 n = 22
S G T G A 72.7
A A K A A 4.5
S G K A A 9.1
S G K G A 13.6
*Single letter amino acid denoting the wild type and point mutations are
indicated with italics. The wild type allele of pfdhfr is ANCSI and pfdhps is SAKAA.isolates had the SGKGA allele, which was previously the
most common allele (76%) in Sabah [4]. A novel point
mutation at position 540 from lysine (K) to threonine (T),
instead of glutamic acid (E) was prevalent in Sabah
(72.7%). K540T point mutation is unique to P. falciparum
isolates in Sabah. It is noteworthy that K540E was
reported in Sabah in the previous study but was absent in
this study. Besides, one isolate had mutation at S436A,
which is also novel to Sabah P. falciparum isolates.
Discussion
Single or multiple mutations at residues A16V, N51I,
C59R, S108N and I164L of pfdhfr have been reported to
be associated with resistance to antifolate drugs in
falciparum malaria treatment. Of these, mutations at
N51I, C59R, S108N and I164L were shown to correlate
with resistance to pyrimethamine [5,11]. Mutation at
A16V was specifically associated with cycloguanil resist-
ance [12]. Mutation at S108N was thought to be the first
event which resulted in reduce in vitro responsiveness to
pyrimethamine, followed by point mutation at N51I and/
or C59R and finally at position I164L. A previous report
implicated that an accumulation of mutations were associ-
ated with increasing resistance to pyrimethamine [11]. In
this study, 86.4% of the P. falciparum isolates had triple
mutations at C59R, S108N and I164L (ACNRNL). In
accordance with the previous study, all of the isolates
showed mutation S108N as expected in populations where
SDX/PYR has been used extensively. However, in contrast
to the previous study that showed 2% prevalence of wild
type allele at codon 59 [5], there was no wild type allele at
this position in the current study.
Triple mutations involving the residue I164L were
commonly found in areas with high levels of clinical re-
sistance to SDX/PYR [5]. It is worth noting that even
though mutation at A16V was not detected in the
present study, the presence of triple mutation at C59R,
S108N and I164L could provide cross-resistance to
cycloguanil [13,14]. Cycloguanil is the active metabolite
of proguanil, an antifolate drug that is commonly used
in the prophylaxis of P. falciparum malaria. Prophylactic
Table 3 Allele combinations of pfdhfr and pfdhps in
Plasmodium falciparum isolates from the interior division
of Sabah, Malaysian Borneo





*Single letter amino acid denoting the wild type and point mutations are
indicated with italics.
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1950s and it is used in combination with atovaquone as
prophylaxis by travellers to Malaysia.
A previous study showed that double mutation at C59R
and S108N was prevalent in Sabah and predicted not to
cause clinical resistance to pyrimethamine [4]. Recently,
studies conducted in Angola and Iran also reported that
double mutation at residues C59R and S108N are more
likely to act as a predictor for the development of resist-
ance to antifolate drugs [15,16]. Taking this into consider-
ation, additional mutation at residue I164L found in this
study at high prevalence could be the pivotal mutation
that causes clinical resistance of P. falciparum to SDX/
PYR therapy in Sabah. Previous report showed that the
presence of three dhfr point mutations were correlated
with clinical resistance to SDX/PYR, regardless of dhps
alleles [4].
In pfdhps, mutation at position A437G is associated with
sulphonamide resistance, while additional point mutations
at S436A, K540E, A581G and A613S might increase the
degree of resistance. Plasmodium falciparum, harbouring
double mutations at residues A437G and K540E (SGEAA),
were known to be associated with resistance to sulpha-
doxine [17,18]. In Sabah, allele SGKGA was predomin-
ant ten years ago, while the current finding showed only
approximately 14% (3/22) allele SGKGA. Additional
mutation at K540T that gave rise to allele SGTGA was
the most prevalent allele (72.7%). Mutation at K540T is
unique to the P. falciparum isolates from Sabah, as
amino acid change from lysine to glutamic acid (K540E)
was commonly found. High prevalence of K540T in
P. falciparum isolates in this region due to the nonsy-
nonymous amino acid substitution (AAA → ACA) in-
stead of K540E (AAA → GAA) need to be highlighted.
Plasmodium falciparum isolates carrying 540 T have
replaced isolates with 540E within the timeframe of a
decade. High prevalence of 540 T and absence of 540E
indicating that this codon has high tendency subjecting
to natural selection and might enhance the drug resistance
pressure of P. falciparum carrying this mutation. Besides,
recent studies reported a change from lysine to asparagine
(K540N) at a few geographical locations, indicating muta-
tions at codon 540 are more likely to change to different
amino acids [19,20]. In this study, mutation at K540T
occurred as a result of non-synonymous mutation at
nucleotides coding for lysine (AAA) to threonine
(ACA). Triple mutations at residues S436A, K540T and
A581G (SGTGA) could contribute to the resistance to
sulphadoxine in Sabah, thus decreasing the efficacy of
SDX/PYR. One novel allele (AAKAA) involving muta-
tion at residue S436A was found in one of the isolates
and is not thought to cause resistance to sulphadoxine.
This allele is sometime referred as wild type allele in a
previous report [21].A four-allele combination of pfdhfr-pfdhps, namely
ANRNI-SGKAA, AIRNI-AAKAA, ANRNL-SGKGA and
ANRNL-SGTGA were formed in this study (Table 3).
The sextuple mutations (ANRNL-SGTGA), which com-
prise triple mutations in both genes, are most prevalent
(72.7%) in Sabah. Overall, the present study reported a
progressive mutation in dhfr and dhps of P. falciparum
isolates in the interior division of Sabah, where triple
mutations are now prevalent in both genes compared to
the previous study with double mutations on both genes.
A sextuple allele combination of pfdhfr-pfdhps is associ-
ated with high-grade clinical resistance to SDX/PYR,
which was found mainly in Africa [22,23]. The other
three alleles found in Sabah range from triple mutation
to quintuple mutations (ANRNI-SGKAA, AIRNI-AAKAA,
ANRNL-SGKGA), which could modulate varying degree of
resistance to SDX/PYR therapy.
Conclusions
This preliminary study showed that mutations in pfdhfr
and pfdhps, which are associated with SDX/PYR resist-
ance are now prevalent in Sabah. The spread of resist-
ant P. falciparum to SDX/PYR in Sabah making this
drug combination is no longer effective in combating
P. falciparum in this geographical region. This report
also confirms that treatment with this combination is
unlikely to be effective and should thus be discontin-
ued. Artemisinin-based combination therapy (artesunate/
mefloquine or artemether/lumefantrine) should continue
to be used as the preferred treatment for falciparum
malaria. Further study is required to elucidate the close
relationship of these mutations with the susceptibility of
P. falciparum isolates to SDX/PYR in Sabah.
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